Innovative Medicine
-
EDURANT® (Rilpivirine) Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) For Use in Treatment-Naïve Adults with HIV-1
Third HIV medication submitted by Tibotec -
REMICADE® Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative Colitis
Approval Expands Access to REMICADE for Children Living with Ulcerative Colitis -
Health Canada Approves Expanded Indication For SIMPONI®* To Include Inhibition Of Structural Damage In The Treatment Of Moderately To Severely Active Rheumatoid Arthritis
SIMPONI® Indication Also Expanded To Include Improvement In Physical Function -
INCIVO® (Telaprevir) Approved In Europe Offering Higher Cure Rates For Genotype-1 Chronic Hepatitis C Compared To Standard Treatment
New treatment options increase chance of a cure -
24 Week Incivo® (Telaprevir)-Based Regimen Effective For Majority Of Previously Untreated Genotype-1 Chronic HCV Patients
ILLUMINATE Phase 3 Study Published In New England Journal Of Medicine -
Johnson & Johnson Symposium Honors 2011 Recipient Of The Dr. Paul Janssen Award For Biomedical Research
Ferrara Honored For Unlocking Key To Novel Anti-Angiogenesis Therapies -
-
-
Zytiga® Approved In The European Union For Metastatic Castration-Resistant Prostate Cancer
First once-daily, oral treatment inhibits androgen production at all sources